PCM
AUTL

Prelude Capital Management’s Autolus Therapeutics AUTL Stock Holding History

Prelude Capital Management’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-27,200
Closed -$37.5K – 1249
2026
Q1 		$37.5K Sell
27,200
-4,808
-15% -$7.3K ﹤0.01% 1141
2025
Q4 		$63.7K Sell
32,008
-39,153
-55% -$60.2K ﹤0.01% 1222
2025
Q3 		$116K Sell
71,161
-38,266
-35% -$74.8K 0.01% 1035
2025
Q2 		$249K Buy
+109,427
New +$181K 0.02% 695
2024
Q3 		– Sell
-266,692
Closed -$928K – 1276
2024
Q2 		$928K Buy
+266,692
New +$1.15M 0.06% 335
2020
Q1 		– Sell
-460
Closed -$6K – 1436
2019
Q4 		$6K Sell
460
-80
-15% -$1.05K ﹤0.01% 1755
2019
Q3 		$7K Sell
540
-50
-8% -$661 ﹤0.01% 1523
2019
Q2 		$9K Buy
590
+203
+52% +$4.54K ﹤0.01% 1416
2019
Q1 		$12K Sell
387
-7
-2% -$199 ﹤0.01% 1394
2018
Q4 		$13K Sell
394
-30,418
-99% -$1M ﹤0.01% 1314
2018
Q3 		$945K Buy
30,812
+18,646
+153% +$503K 0.05% 384
2018
Q2 		$326K Buy
+12,166
New +$321K 0.02% 650

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Prelude Capital Management's AUTL Position: Q2 2026 in Review

Prelude Capital Management sold out of Autolus Therapeutics (AUTL) in Q2 2026, closing a stake of 27,200 shares — an estimated $37.5K sold.

Prelude Capital Management first reported a position in AUTL in Q2 2018 and held it in 12 quarters. The position peaked at $945K in Q3 2018. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Prelude Capital Management reported no remaining Autolus Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Prelude Capital Management sold 27,200 Autolus Therapeutics shares in Q2 2026, an estimated $37.5K.
  • Prelude Capital Management first reported a position in Autolus Therapeutics in Q2 2018 and held it in 12 quarters.
  • Prelude Capital Management's Autolus Therapeutics position peaked at $945K in Q3 2018.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.